Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

NCT02833948 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

231

Enrollment

INDUSTRY

Sponsor class

Conditions

Aortic Valve Stenosis
Cardiovascular Diseases
Heart Valve Diseases
Ventricular Outflow Obstruction
Thrombosis

Interventions

DRUG: Acetylsalicylic acid
DRUG: Clopidogrel
DRUG: Rivaroxaban

Sponsor

ECRI bv

Collaborators

[object Object]
[object Object]
[object Object]